Animal Health and Innovation Act of 2018

Bill: 115-hr-5599
Sponsor: full_name: Rep. Hudson, Richard [R-NC-8]
Introduced: 2018-04-24
Policy area: Health
Subjects: Animal and plant health

Animal protection and human-animal relationships

Drug safety, medical device, and laboratory regulation
Latest action: action_date: 2018-04-24
text: Referred to the House Committee on Energy and Commerce.

Summaries:
action_date: 2018-04-24
action_desc: Introduced in House
text: <p><b>Animal Health and Innovation Act of 2018 </b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to expand the authority of the Food and Drug Administration to conditionally approve a new animal drug that (1)is intended to treat a serious or life-threatening disease or condition or address an unmet animal or human health need, and (2)a demonstration of effectiveness would require a complex or particularly difficult study or studies.</p>

tv_txt: I 115th CONGRESS 2d Session H. R. 5599 IN THE HOUSE OF REPRESENTATIVES April 24, 2018 Mr. Hudson (for himself, Mr. Schrader , Mr. Bucshon , Mr. Butterfield , and Mr. Mullin ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to expand the conditional approval pathway for more animal drugs, and for other purposes.

1. Short title This Act may be cited as the Animal Health and Innovation Act of 2018 . 2. Conditional approval of new animal drugs Section 571 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360ccc ) is amended— (1) in the section heading, by striking species and inserting species and certain new animal drugs ; (2) in subsection (a)— (A) by amending paragraph (1) to read as follows: (1) (A) Except as provided in paragraph (3), any person may file with the Secretary an application for conditional approval of— (i) a new animal drug intended for a minor use or a minor species; or (ii) a new animal drug not intended for a minor use or minor species— (I) that is intended to treat a serious or life-threatening disease or condition or addresses an unmet animal or human health need; and (II) for which the Secretary determines that a demonstration of effectiveness would require a complex or particularly difficult study or studies. (B) The Secretary shall, not later than September 30, 2019, issue guidance or regulations further clarifying the criteria specified in subparagraph (A)(ii). (C) An application under this paragraph shall comply in all respects with the provisions of section 512 except for subsections (a)(4), (b)(2), (c)(1), (c)(2), (c)(3), (d)(1), (e), (h), and (n) of such section unless otherwise stated in this section, and any additional provisions of this section. (D) New animal drugs conditionally approved under this section are subject to application of the same safety standards that would be applied to new animal drugs approved under section 512(d) (including, for antimicrobial new animal drugs, with respect to antimicrobial resistance). ; and (B) in paragraph (3)— (i) in subparagraph (A), by striking the period at the end and inserting or a new animal drug that is an antibiotic drug; ; and (ii) in subparagraph (B), by striking ; or and inserting ; or ; and (3) in subsection (f)— (A) in paragraph (1), in the matter preceding subparagraph (A), by inserting for the conditionally approved use after shall ; and (B) in paragraph (2)— (i) by striking An intended use and inserting The Secretary shall, through regulation or guidance, determine under what conditions an intended use ; and (ii) by striking shall not and inserting may .